{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T17:57:59Z","timestamp":1781632679016,"version":"3.54.5"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T00:00:00Z","timestamp":1769817600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T00:00:00Z","timestamp":1773792000000},"content-version":"vor","delay-in-days":46,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["21834002"],"award-info":[{"award-number":["21834002"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The treatment of triple-negative breast cancer (TNBC) remains challenging. Conventional anti-angiogenic therapies, which aim to disrupt the tumor\u2019s blood supply, are often hampered by limited efficacy and drug resistance. Innovative strategies that specifically target the unique phenotype of tumor vascular endothelial cells (TVECs) are urgently needed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We developed peroxide-treated hybrid membrane bio-nanovesicles (ox-HyV) by fusing membranes from human induced pluripotent stem cell-derived endothelial cells (iPSC-ECs) and breast cancer cells. The vesicles were characterized for size, morphology, and protein composition. Their targeting efficiency to TVECs was validated both in vitro and in vivo using immunofluorescence and small animal imaging. The functional effects on TVEC secretion, cGAS-STING pathway activation, and immune cell recruitment were assessed via ELISA, western blot, flow cytometry, and immunofluorescence. The anti-tumor efficacy and survival benefit were evaluated in a murine TNBC model.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>ox-HyVs specifically targeted and were internalized by TVECs. They reprogrammed the secretory phenotype of TVECs by delivering key molecular cargoes, notably miR-429, which subsequently downregulated Bcl2 and activated the cGAS-STING pathway. This activation triggered a robust innate immune response and promoted the infiltration of cytotoxic T cells into tumors. In vivo, treatment with ox-HyVs significantly inhibited tumor growth and extended survival in a TNBC mouse model.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>We have developed a novel bio-nanovesicle, ox-HyV, that represents a significant advancement over previous hybrid membrane systems. Unlike conventional hybrid vesicles designed primarily for drug delivery, ox-HyV is engineered through peroxidation to be intrinsically immunogenic, enabling it to directly reprogram the tumor vasculature and activate the cGAS-STING pathway via its endogenous miRNA cargo. This self-adjuvating, multimodal mechanism effectively converts the immunosuppressive tumor microenvironment into an immunoreactive one. Our study not only presents a potent new therapeutic candidate but also establishes a broadly applicable platform technology for vascular-targeted immunotherapy, with strong promise for clinical translation in TNBC and other solid tumors.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12967-026-07716-y","type":"journal-article","created":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T10:35:01Z","timestamp":1769855701000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Hybrid bioinspired nanovescicles target tumor endothelial cells and regulate immuno-microenvironment for triple-negative breast cancer therapy"],"prefix":"10.1186","volume":"24","author":[{"given":"Zhengwei","family":"Gui","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiyang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,31]]},"reference":[{"key":"7716_CR1","doi-asserted-by":"crossref","unstructured":"Wang Y, Lyu Y, Tu K, Xu Q, Yang Y, Salman S, et al. Histone citrullination by PADI4 is required for HIF-dependent transcriptional responses to hypoxia and tumor vascularization. Sci Adv. 2021;7(35).","DOI":"10.1126\/sciadv.abe3771"},{"issue":"8","key":"7716_CR2","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1200\/JCO.2007.14.4147","volume":"26","author":"C Liedtke","year":"2008","unstructured":"Liedtke C, Mazouni C, Hess KR, Andre F, Tordai A, Mejia JA, et al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol. 2008;26(8):1275\u201381.","journal-title":"J Clin Oncol"},{"issue":"15","key":"7716_CR3","doi-asserted-by":"publisher","first-page":"1796","DOI":"10.1200\/JCO.2011.38.8595","volume":"30","author":"G von Minckwitz","year":"2012","unstructured":"von Minckwitz G, Untch M, Blohmer JU, Costa SD, Eidtmann H, Fasching PA, et al. Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J Clin Oncol. 2012;30(15):1796\u2013804.","journal-title":"J Clin Oncol"},{"issue":"4","key":"7716_CR4","doi-asserted-by":"publisher","first-page":"1785","DOI":"10.1172\/JCI96313","volume":"129","author":"T Gruosso","year":"2019","unstructured":"Gruosso T, Gigoux M, Manem VSK, Bertos N, Zuo D, Perlitch I, et al. Spatially distinct tumor immune microenvironments stratify triple-negative breast cancers. J Clin Invest. 2019;129(4):1785\u2013800.","journal-title":"J Clin Invest"},{"issue":"10","key":"7716_CR5","doi-asserted-by":"publisher","first-page":"1694","DOI":"10.1016\/j.cell.2022.03.033","volume":"185","author":"P Baldominos","year":"2022","unstructured":"Baldominos P, Barbera-Mourelle A, Barreiro O, Huang Y, Wight A, Cho JW, et al. Quiescent cancer cells resist T cell attack by forming an immunosuppressive niche. Cell. 2022;185(10):1694\u2013708. e19.","journal-title":"Cell"},{"issue":"1","key":"7716_CR6","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1186\/s13046-018-1002-1","volume":"37","author":"Y He","year":"2018","unstructured":"He Y, Jiang Z, Chen C, Wang X. Classification of triple-negative breast cancers based on Immunogenomic profiling. J Exp Clin Cancer Res. 2018;37(1):327.","journal-title":"J Exp Clin Cancer Res"},{"issue":"9","key":"7716_CR7","doi-asserted-by":"publisher","first-page":"e985930","DOI":"10.4161\/2162402X.2014.985930","volume":"4","author":"S Adams","year":"2015","unstructured":"Adams S, Goldstein LJ, Sparano JA, Demaria S, Badve SS. Tumor infiltrating lymphocytes (TILs) improve prognosis in patients with triple negative breast cancer (TNBC). Oncoimmunology. 2015;4(9):e985930.","journal-title":"Oncoimmunology"},{"issue":"16","key":"7716_CR8","doi-asserted-by":"publisher","first-page":"5002","DOI":"10.1158\/1078-0432.CCR-18-3524","volume":"25","author":"Y Xiao","year":"2019","unstructured":"Xiao Y, Ma D, Zhao S, Suo C, Shi J, Xue MZ, et al. Multi-Omics profiling reveals distinct microenvironment characterization and suggests immune escape mechanisms of Triple-Negative breast cancer. Clin Cancer Res. 2019;25(16):5002\u201314.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"7716_CR9","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.ccell.2020.12.001","volume":"39","author":"A Bagati","year":"2021","unstructured":"Bagati A, Kumar S, Jiang P, Pyrdol J, Zou AE, Godicelj A, et al. Integrin alphavbeta6-TGFbeta-SOX4 pathway drives immune evasion in Triple-Negative breast cancer. Cancer Cell. 2021;39(1):54\u2013e679.","journal-title":"Cancer Cell"},{"issue":"5","key":"7716_CR10","first-page":"101064","volume":"20","author":"J Zhang","year":"2025","unstructured":"Zhang J, Xian P, Wang C, Pan X, Du Y, Nan Y, et al. Penetrative biomimetic nanovehicle boosts immunotherapy in triple-negative breast cancer via SOS1 Blockade. Asian J Pharm Sci. 2025;20(5):101064.","journal-title":"Asian J Pharm Sci"},{"issue":"4","key":"7716_CR11","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1007\/s12032-023-01965-3","volume":"40","author":"GR Antony","year":"2023","unstructured":"Antony GR, Littleflower AB, Parambil ST, Subhadradevi L. PD-1\/PD-L1 Blockade inhibits epithelial-mesenchymal transition and improves chemotherapeutic response in breast cancer. Med Oncol. 2023;40(4):108.","journal-title":"Med Oncol"},{"key":"7716_CR12","doi-asserted-by":"publisher","first-page":"107926","DOI":"10.1016\/j.compbiomed.2024.107926","volume":"169","author":"PW Liu","year":"2024","unstructured":"Liu PW, Lin J, Hou R, Cai Z, Gong Y, He PA, et al. Single-cell RNA-seq reveals the metabolic status of immune cells response to immunotherapy in triple-negative breast cancer. Comput Biol Med. 2024;169:107926.","journal-title":"Comput Biol Med"},{"issue":"4","key":"7716_CR13","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1158\/2767-9764.CRC-23-0548","volume":"4","author":"P Hirani","year":"2024","unstructured":"Hirani P, McDermott J, Rajeeve V, Cutillas PR, Jones JL, Pennington DJ, et al. Versican associates with tumor immune phenotype and limits T-cell trafficking via chondroitin sulfate. Cancer Res Commun. 2024;4(4):970\u201385.","journal-title":"Cancer Res Commun"},{"issue":"10","key":"7716_CR14","doi-asserted-by":"publisher","first-page":"e0224015","DOI":"10.1371\/journal.pone.0224015","volume":"14","author":"K Petrovic","year":"2019","unstructured":"Petrovic K, Robinson J, Whitworth K, Jinks E, Shaaban A, Lee SP. TEM8\/ANTXR1-specific CAR T cells mediate toxicity in vivo. PLoS ONE. 2019;14(10):e0224015.","journal-title":"PLoS ONE"},{"issue":"2","key":"7716_CR15","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1158\/0008-5472.CAN-16-1911","volume":"78","author":"TT Byrd","year":"2018","unstructured":"Byrd TT, Fousek K, Pignata A, Szot C, Samaha H, Seaman S, et al. TEM8\/ANTXR1-Specific CAR T cells as a targeted therapy for Triple-Negative breast cancer. Cancer Res. 2018;78(2):489\u2013500.","journal-title":"Cancer Res"},{"key":"7716_CR16","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.canlet.2019.11.003","volume":"482","author":"T Pan","year":"2020","unstructured":"Pan T, Zhou D, Shi Z, Qiu Y, Zhou G, Liu J, et al. Centromere protein U (CENPU) enhances angiogenesis in triple-negative breast cancer by inhibiting ubiquitin-proteasomal degradation of COX-2. Cancer Lett. 2020;482:102\u201311.","journal-title":"Cancer Lett"},{"issue":"1","key":"7716_CR17","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1158\/2326-6066.CIR-20-0527","volume":"9","author":"JP Vayrynen","year":"2021","unstructured":"Vayrynen JP, Haruki K, Lau MC, Vayrynen SA, Zhong R, Dias Costa A, et al. The prognostic role of macrophage polarization in the colorectal cancer microenvironment. Cancer Immunol Res. 2021;9(1):8\u201319.","journal-title":"Cancer Immunol Res"},{"key":"7716_CR18","doi-asserted-by":"crossref","unstructured":"Garrido-Martin EM, Mellows TWP, Clarke J, Ganesan AP, Wood O, Cazaly A, et al. M1(hot) tumor-associated macrophages boost tissue-resident memory T cells infiltration and survival in human lung cancer. J Immunother Cancer. 2020;8(2).","DOI":"10.1136\/jitc-2020-000778"},{"issue":"8","key":"7716_CR19","doi-asserted-by":"publisher","first-page":"e239","DOI":"10.1002\/ctm2.239","volume":"10","author":"E Strack","year":"2020","unstructured":"Strack E, Rolfe PA, Fink AF, Bankov K, Schmid T, Solbach C, et al. Identification of tumor-associated macrophage subsets that are associated with breast cancer prognosis. Clin Transl Med. 2020;10(8):e239.","journal-title":"Clin Transl Med"},{"issue":"7","key":"7716_CR20","doi-asserted-by":"publisher","first-page":"11076","DOI":"10.1021\/acsnano.2c03781","volume":"16","author":"Y Cui","year":"2022","unstructured":"Cui Y, Li Z, Guo Y, Qi X, Yang Y, Jia X, et al. Bioinspired nanovesicles convert the skeletal Endothelium-Associated secretory phenotype to treat osteoporosis. ACS Nano. 2022;16(7):11076\u201391.","journal-title":"ACS Nano"},{"issue":"43","key":"7716_CR21","doi-asserted-by":"publisher","first-page":"9581","DOI":"10.1002\/adma.201602173","volume":"28","author":"H Sun","year":"2016","unstructured":"Sun H, Su J, Meng Q, Yin Q, Chen L, Gu W, et al. Cancer-Cell-Biomimetic nanoparticles for targeted therapy of homotypic tumors. Adv Mater. 2016;28(43):9581\u20138.","journal-title":"Adv Mater"},{"key":"7716_CR22","doi-asserted-by":"publisher","first-page":"102068","DOI":"10.1016\/j.omtn.2023.102068","volume":"34","author":"K Radloff","year":"2023","unstructured":"Radloff K, Gutbier B, Dunne CM, Moradian H, Schwestka M, Gossen M, et al. Cationic LNP-formulated mRNA expressing Tie2-agonist in the lung endothelium prevents pulmonary vascular leakage. Mol Ther Nucleic Acids. 2023;34:102068.","journal-title":"Mol Ther Nucleic Acids"},{"issue":"6","key":"7716_CR23","doi-asserted-by":"publisher","first-page":"e2306156","DOI":"10.1002\/advs.202306156","volume":"11","author":"Z Gu","year":"2024","unstructured":"Gu Z, Sun M, Liu J, Huang Q, Wang Y, Liao J, et al. Endothelium-Derived engineered extracellular vesicles protect the pulmonary endothelial barrier in acute lung injury. Adv Sci (Weinh). 2024;11(6):e2306156.","journal-title":"Adv Sci (Weinh)"},{"key":"7716_CR24","doi-asserted-by":"publisher","first-page":"6955","DOI":"10.2147\/IJN.S436350","volume":"18","author":"J Yang","year":"2023","unstructured":"Yang J, Zhang X, Wang G, Ma S, Yu Y, Liao C, et al. ApoSEVs-Mediated modulation of versatile target cells promotes diabetic wound healing: unveiling a promising strategy. Int J Nanomed. 2023;18:6955\u201377.","journal-title":"Int J Nanomed"},{"key":"7716_CR25","first-page":"1","volume":"18","author":"L Zhang","year":"2022","unstructured":"Zhang L, Qin Z, Sun H, Chen X, Dong J, Shen S, et al. Nanoenzyme engineered neutrophil-derived exosomes attenuate joint injury in advanced rheumatoid arthritis via regulating inflammatory environment. Bioact Mater. 2022;18:1\u201314.","journal-title":"Bioact Mater"},{"issue":"23","key":"7716_CR26","doi-asserted-by":"publisher","first-page":"e2109517","DOI":"10.1002\/adma.202109517","volume":"34","author":"J Yan","year":"2022","unstructured":"Yan J, Liu X, Wu F, Ge C, Ye H, Chen X, et al. Platelet pharmacytes for the hierarchical amplification of antitumor immunity in response to Self-Generated immune signals. Adv Mater. 2022;34(23):e2109517.","journal-title":"Adv Mater"},{"issue":"43","key":"7716_CR27","doi-asserted-by":"publisher","first-page":"e2300544","DOI":"10.1002\/smll.202300544","volume":"19","author":"EJ Go","year":"2023","unstructured":"Go EJ, Yang H, Park W, Lee SJ, Han JH, Kong SJ, et al. Systemic delivery of a STING Agonist-Loaded positively charged liposome selectively targets tumor immune microenvironment and suppresses tumor angiogenesis. Small. 2023;19(43):e2300544.","journal-title":"Small"},{"key":"7716_CR28","doi-asserted-by":"crossref","unstructured":"Chelvanambi M, Fecek RJ, Taylor JL, Storkus WJ. STING agonist-based treatment promotes vascular normalization and tertiary lymphoid structure formation in the therapeutic melanoma microenvironment. J Immunother Cancer. 2021;9(2).","DOI":"10.1136\/jitc-2020-001906"},{"issue":"1","key":"7716_CR29","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1186\/s12951-025-03161-z","volume":"23","author":"LY Yang","year":"2025","unstructured":"Yang LY, Liang GW, Cai BJ, Xu KM, Zhao YJ, Xie XT, et al. Enhanced tumor self-targeting of lemon-derived extracellular vesicles by embedding homotypic cancer cell membranes for efficient drug delivery. J Nanobiotechnol. 2025;23(1):74.","journal-title":"J Nanobiotechnol"},{"issue":"31","key":"7716_CR30","doi-asserted-by":"publisher","first-page":"e2311702","DOI":"10.1002\/smll.202311702","volume":"20","author":"C Zhao","year":"2024","unstructured":"Zhao C, Pan Y, Liu L, Zhang J, Wu X, Liu Y, et al. Hybrid cellular nanovesicles block PD-L1 signal and repolarize M2 macrophages for cancer immunotherapy. Small. 2024;20(31):e2311702.","journal-title":"Small"},{"key":"7716_CR31","doi-asserted-by":"crossref","unstructured":"Paschoal Barbosa LM, Gomes ER, Barros ALB, Cassali GD, Carvalho AT, Silva JO, et al. Hybrid nanosystem formed by DOX-loaded liposomes and extracellular vesicles from MDA-MB-231 is effective against breast cancer cells with different molecular profiles. Pharmaceutics. 2024;16(6).","DOI":"10.3390\/pharmaceutics16060739"},{"issue":"11","key":"7716_CR32","doi-asserted-by":"publisher","first-page":"2314","DOI":"10.1038\/s41418-019-0302-0","volume":"26","author":"CX Zhang","year":"2019","unstructured":"Zhang CX, Ye SB, Ni JJ, Cai TT, Liu YN, Huang DJ, et al. STING signaling remodels the tumor microenvironment by antagonizing myeloid-derived suppressor cell expansion. Cell Death Differ. 2019;26(11):2314\u201328.","journal-title":"Cell Death Differ"},{"issue":"1","key":"7716_CR33","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1186\/s12943-019-1087-y","volume":"18","author":"Y Zhu","year":"2019","unstructured":"Zhu Y, An X, Zhang X, Qiao Y, Zheng T, Li X. STING: a master regulator in the cancer-immunity cycle. Mol Cancer. 2019;18(1):152.","journal-title":"Mol Cancer"},{"key":"7716_CR34","doi-asserted-by":"crossref","unstructured":"Hato L, Vizcay A, Eguren I, Perez-Gracia JL, Rodriguez J, Gallego Perez-Larraya J, et al. Dendritic cells cancer immunol immunotherapy cancers (Basel). 2024;16(5).","DOI":"10.3390\/cancers16050981"},{"key":"7716_CR35","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.actbio.2024.12.059","volume":"193","author":"Y Pan","year":"2025","unstructured":"Pan Y, Qu H, Chen H, Cheng W, Duan Z, Yang J, et al. A tumor-targeting porphyrin-micelle with enhanced STING agonist delivery and synergistic photo-\/immuno- therapy for cancer treatment. Acta Biomater. 2025;193:377\u201391.","journal-title":"Acta Biomater"},{"issue":"8","key":"7716_CR36","doi-asserted-by":"publisher","first-page":"4610","DOI":"10.1039\/D4NR03054K","volume":"17","author":"J Yang","year":"2025","unstructured":"Yang J, Chen M, Li R, Sun Y, Ye P, Fang K, et al. A responsive cocktail nano-strategy breaking the immune excluded state enhances immunotherapy for triple negative breast cancer. Nanoscale. 2025;17(8):4610\u201323.","journal-title":"Nanoscale"},{"key":"7716_CR37","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/j.actbio.2025.01.038","volume":"194","author":"Z Zhou","year":"2025","unstructured":"Zhou Z, Guo F, Zhang J, Liao L, Jiang M, Huang Y, et al. Facile integration of a binary nano-prodrug with alphaPD-L1 as a translatable technology for potent immunotherapy of TNBC. Acta Biomater. 2025;194:373\u201384.","journal-title":"Acta Biomater"},{"issue":"4","key":"7716_CR38","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1038\/s41419-021-03587-x","volume":"12","author":"T Baba","year":"2021","unstructured":"Baba T, Yoshida T, Tanabe Y, Nishimura T, Morishita S, Gotoh N, et al. Cytoplasmic DNA accumulation preferentially triggers cell death of myeloid leukemia cells by interacting with intracellular DNA sensing pathway. Cell Death Dis. 2021;12(4):322.","journal-title":"Cell Death Dis"},{"key":"7716_CR39","doi-asserted-by":"publisher","first-page":"120242","DOI":"10.1016\/j.lfs.2021.120242","volume":"289","author":"Y Zhang","year":"2022","unstructured":"Zhang Y, Ding C, Zhu W, Li X, Chen T, Liu Q, et al. Chemotherapeutic drugs induce oxidative stress associated with DNA repair and metabolism modulation. Life Sci. 2022;289:120242.","journal-title":"Life Sci"},{"issue":"9","key":"7716_CR40","doi-asserted-by":"publisher","first-page":"2519","DOI":"10.4049\/jimmunol.2000487","volume":"205","author":"M Kohno","year":"2020","unstructured":"Kohno M, Murakami J, Wu L, Chan ML, Yun Z, Cho BCJ, et al. Foxp3(+) regulatory T cell depletion after nonablative oligofractionated irradiation boosts the abscopal effects in murine malignant mesothelioma. J Immunol. 2020;205(9):2519\u201331.","journal-title":"J Immunol"},{"key":"7716_CR41","doi-asserted-by":"publisher","first-page":"104745","DOI":"10.1016\/j.phrs.2020.104745","volume":"155","author":"B Farhood","year":"2020","unstructured":"Farhood B, Khodamoradi E, Hoseini-Ghahfarokhi M, Motevaseli E, Mirtavoos-Mahyari H, Eleojo Musa A, et al. TGF-beta in radiotherapy: mechanisms of tumor resistance and normal tissues injury. Pharmacol Res. 2020;155:104745.","journal-title":"Pharmacol Res"},{"key":"7716_CR42","doi-asserted-by":"crossref","unstructured":"Anders CK, Woodcock MG, Van Swearingen AED, Moore DT, Sambade MJ, Laurie S, et al. Evaluating the efficacy of a priming dose of cyclophosphamide prior to pembrolizumab to treat metastatic triple negative breast cancer. J Immunother Cancer. 2022;10(2).","DOI":"10.1136\/jitc-2021-003427"},{"issue":"7","key":"7716_CR43","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1097\/CM9.0000000000000710","volume":"133","author":"J Zhao","year":"2020","unstructured":"Zhao J, Huang J. Breast cancer immunology and immunotherapy: targeting the programmed cell death protein-1\/programmed cell death protein ligand-1. Chin Med J (Engl). 2020;133(7):853\u201362.","journal-title":"Chin Med J (Engl)"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12967-026-07716-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-026-07716-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-026-07716-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T17:27:18Z","timestamp":1781630838000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12967-026-07716-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,31]]},"references-count":43,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["7716"],"URL":"https:\/\/doi.org\/10.1186\/s12967-026-07716-y","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,31]]},"assertion":[{"value":"14 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All animal experiments were conducted in accordance with protocols approved by the Animal Care and Use Committee of Tongji Hospital of Tongji Medical College of Huazhong University of Science and Technology (Approval document: TJ-23366). All necessary ethical regulations were strictly adhered to during the experiments. Breast cancer specimens from the patient were procured through the Department of Pathology at Tongji Hospital, with informed consent duly obtained.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"383"}}